PBBM and PBPK modeling are increasingly central to mechanistic understanding of drug absorption and systemic exposure. By linking critical material attributes, process parameters, and physiological variables, these approaches enable quantitative prediction of in vivo performance, virtual bioequivalence, and biowaiver strategies. This session will highlight recent advances in model-informed drug development (MIDD), including applications in complex formulations, nonlinear absorption, and regulatory decision-making.
